GnRH
Synthetic version of natural GnRH that stimulates pituitary release of LH and FSH. Used for fertility and hormone testing.
Regulatory status (as of Sept 2026)
Human-use brands discontinued in the US; veterinary gonadorelin products remain FDA-approved (CVM). Its current compounding (503A) status has not been verified for this page.
See the FDA peptide regulatory tracker · Read our July 27, 2026 dispatch on the FDA PCAC peptide vote2 studies referenced · Last reviewed Oct 1, 2026 · Reviewed by The Peptide Dispatch Editorial Team · How we research & label content
Gonadorelin is a compound whose development or US marketing has been discontinued. Synthetic version of natural GnRH that stimulates pituitary release of LH and FSH.
| Half-life | Not established in published research |
|---|---|
| How it's given in studies | Subcutaneous injection |
| Research stage | Discontinued |
| Dosing | Published research: No published human dosing detailsThe published dosing studies found are veterinary: 100 vs 200 µg i.m. gonadorelin HCl in dairy cows/heifers; 60 µg/kg in fish. No published human dosing study was found.Community-reportedCommunity-reported: 100–500 mcg, subcutaneous injection |
Published-research dosing is what was given in the cited studies (species and units as reported). Community-reported dosing is what users describe, not from clinical studies. Neither is a recommendation. Not medical advice.
Where each point comes from: Clinicalhuman trials and FDA labels Lab / animalrodent, cell and ex vivo studies Community-reporteduser experience and commonly used protocols, not from clinical studies
In plain terms: It is a copy of the brain hormone that tells the pituitary gland to release reproductive hormones. Activates GnRH receptors in pituitary to release gonadotropins in pulsatile manner.
How to read this: Each item below is an effect observed in research subjects in the cited studies — think of Dexter, our stand-in research subject. These are findings from the literature, not results you should expect, and not medical advice.
Community-reportedCommonly reported doses range from 100 to 500 mcg (subcutaneous injection). This is not a recommendation.
Community reports are anecdotal, vary widely in product quality and purity, and are not medical advice. Talk to a licensed provider.
New research, FDA peptide updates, and what users are reporting. One email a week. Unsubscribe anytime.
| Peptide | Half-Life | Route | Research Status |
|---|---|---|---|
| Gonadorelin | No published PK data found | Subcutaneous injection | Discontinued |
| Kisspeptin-10 | Kisspeptin-10: ~4 min (mice, IV/systemic); ~28 min (27.6 ± 1.1) is kisspeptin-54 in human males (IV infusion) | Subcutaneous or IV injection | Phase 1 / early human |
| PT-141 (Bremelanotide) | No published PK data found | Subcutaneous injection | FDA-approved |
| Triptorelin | Geometric mean terminal half-life 2.8 h in healthy males after a 0.5 mg IV bolus; 6.6-7.7 h in males with renal or hepatic impairment (three-compartment model) | Intramuscular injection | FDA-approved |
Values reflect figures reported in published research. Compare any peptides side-by-side →
This peptide belongs to the Sexual Health category. View All Sexual Health Peptides
From Our Affiliated Clinic
1836 Wellness is a physician-supervised clinic in Houston, TX. Discussing a compound on this page is not an offer to prescribe or supply it.
See how it works →Disclosure: The Peptide Dispatch and 1836 Wellness are commonly owned by 1836 Wellness LLC. We may benefit financially if you become a client of 1836 Wellness. Learn more.
Dosing, half-life figures, and mechanism descriptions on this page are compiled from peer-reviewed published research, with the species and study type stated where reported. Figures labeled “Dosing used in published research” describe what was given in those studies and do not constitute dosing recommendations for any human use. Each cited paper is listed with DOI and PubMed links in the References section above. Found an error? Contact us.